The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

BACKGROUND: Empagliflozin is a potent, selective sodium glucose cotransporter 2 (SGLT2) inhibitor in development as an oral antidiabetic treatment. This QT interval study assessed potential effects of empagliflozin on ventricular repolarisation and other electrocardiogram (ECG) parameters. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Ring, Arne, Brand, Tobias, Macha, Sreeraj, Breithaupt-Groegler, Kerstin, Simons, Gudrun, Walter, Beate, Woerle, Hans J, Broedl, Uli C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648489/
https://www.ncbi.nlm.nih.gov/pubmed/23617452
http://dx.doi.org/10.1186/1475-2840-12-70

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648489/
https://www.ncbi.nlm.nih.gov/pubmed/23617452
http://dx.doi.org/10.1186/1475-2840-12-70

Ejemplares similares